Story perspectives

UK Drug Pricing Crisis: Patients Face Limited Access

8/25/2025

24 2

Summary

Story summary

UK Health Secretary Wes Streeting criticized pharmaceutical companies for their shortsightedness in stalled drug pricing negotiations.
A rebate scheme's increase from 15% to nearly 23% is impacting NHS costs and patient access to new medicines.
Drug companies warn that high rebate rates could reduce investment in the UK, limiting innovative treatment availability.
The Association of the British Pharmaceutical Industry states this situation negatively affects NHS patient access and health outcomes.

1 of 1

Story summary

UK Health Secretary Wes Streeting criticized pharmaceutical companies for their shortsightedness in stalled drug pricing negotiations.
A rebate scheme's increase from 15% to nearly 23% is impacting NHS costs and patient access to new medicines.
Drug companies warn that high rebate rates could reduce investment in the UK, limiting innovative treatment availability.
The Association of the British Pharmaceutical Industry states this situation negatively affects NHS patient access and health outcomes.